- Investing Ideas
- Swiss Pharmaceuticals & Biotech Large Cap High Growth Potential
Swiss Pharmaceuticals & Biotech Large Cap High Growth Potential
Results
4
Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.
4 companies
Galderma Group
Market Cap: CHF 33.4b
Operates as a dermatology company worldwide.
GALD
CHF 142.50
7D
-1.9%
1Y
49.8%
Sandoz Group
Market Cap: CHF 25.8b
Develops, manufactures, and markets generic and biosimilars worldwide.
SDZ
CHF 59.66
7D
-4.8%
1Y
55.9%
Novartis
Market Cap: CHF 221.6b
Researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
NOVN
CHF 116.12
7D
-4.4%
1Y
18.3%
Lonza Group
Market Cap: CHF 32.8b
Supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.
LONN
CHF 467.40
7D
-3.1%
1Y
-17.7%